Industry

FOOTHILL RANCH, Calif.–(BUSINESS WIRE)–TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the publication of a study in the September 22 issue of the Journal of Medical Physics that assessed whether alpha particles generated through the combination of boron target drugs and proton radiation would generate … [Read more…]

MENLO PARK, Calif. & DALLAS–(BUSINESS WIRE)–ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that David Lockhart, Ph.D, President and Chief Scientific Officer of ReCode Therapeutics, will present a company overview at 8:00 a.m. ET on Thursday, September 29, 2022 at the … [Read more…]

Board of Directors approves quarterly cash dividend of $0.40 per share NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.40 fourth-quarter 2022 dividend on the company’s common stock, payable December 5, 2022, to holders of the Common Stock of record at the close of business on November 4, … [Read more…]

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that Sekar Kathiresan, M.D., a Maze co-founder, has joined the company’s board of directors. Dr. Kathiresan is an experienced cardiologist, co-founder and chief executive officer of Verve Therapeutics, and a lecturer in medicine at Harvard Medical School. His … [Read more…]

LAWRENCE, Kan.–(BUSINESS WIRE)–#Endpoints11—Endpoints News, the biopharma industry’s leading source for daily news and analysis, today unveiled the 2022 Endpoints 11 — the most promising biotech startup companies of the year. Born during a boom but virtually shunned on Wall Street today, this group of upstarts is out to defy some tough odds in birthing a … [Read more…]

DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Jefferies Cell & Genetic Medicine Summit taking place September 29-30, 2022. Details for the company presentation are as follows: Date: … [Read more…]

LINCOLN, Neb. & NEW YORK–(BUSINESS WIRE)–Paradigm Oral Health (“Paradigm”), a leading oral surgery and digital dentistry platform, today announced that BlackRock Long Term Private Capital (“LTPC”) has entered into a definitive agreement to acquire a majority interest in the company from shareholders including InTandem Capital Partners. LTPC will partner with Paradigm’s executive leadership team, led … [Read more…]

BEDFORD, Mass.–(BUSINESS WIRE)–$OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced multiple presentations at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting being held September 30 – October 3, 2022 at McCormick Place Convention Center in … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Cell-Free RNA Isolation and Extraction Kits Market – A Global and Regional Analysis: Focus on Application, End User, and Region – Analysis and Forecast, 2022-2032” report has been added to ResearchAndMarkets.com’s offering. The global cell-free RNA isolation and extraction kits market is projected to reach $140.7 million by 2032 from $30.2 million in … [Read more…]

SAN DIEGO–(BUSINESS WIRE)–$JANX—Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Winston Kung to the Company’s Board of Directors. Janux also announced that Stefan … [Read more…]